Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab Plus Lenvatinib in Advanced Cervical Cancer
NCT05824468Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zimberelimab, lenvatinib in Cervical Cancer (CC), sponsored by Sun Yat-sen University. Started May 2023; status: active, not recruiting.
02
Drugs
zimberelimablenvatinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05824468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824468.